ARM State of the Industry Briefing at JP Morgan Healthcare Conference 2018

ARM State of the Industry Briefing at JP Morgan Healthcare Conference 2018

Overview

Bob Preti and Janet Lynch Lambert, chairman and CEO of the Alliance for Regenerative Medicine (ARM), presented the “State of the Industry” briefing at the 2018 JP Morgan Healthcare Conference, the premier investment conference for biotech, healthcare, and pharmaceutical industries. ARM’s mission is to advance regenerative medicine. It is a global organization that brings together all stakeholders in the field to accelerate research, development, investments, and commercialization of regenerative therapies and cures. In their presentation, Preti and Lambert summarized recent advances in gene and cell therapy, including R&D, financial and regulatory developments, mergers and acquisitions, and reimbursement challenges. They discussed how the industry has seen an overall increase in investments and regulatory support in 2017. American Gene Technologies (AGT) was highlighted in ARM’s briefing (minute 9:30) on a list of companies and research institutions making advances in immune-oncology, under the category of Gamma-Delta cells. This recognition from ARM, a highly respected multi-stakeholder advocacy organization for the cell and gene therapy and broader regenerative medicine sector, strengthens AGT’s position as a leader in the field of regenerative medicine. AGT is a pioneer in immuno-oncology and has received the first patent for the stimulation of Gamma-Delta T cells for the treatment of solid tumor cancers. To view both the Alliance for Regenerative Medicine’s JP Morgan State of the Industry presentation, please see below. For more information about the Alliance for Regenerative Medicine and its mission, visit: https://alliancerm.org/

Video Recorded Presentation:

Video Recorded Presentation: